Sumitomo Mitsui Trust Group Inc. Purchases 300 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sumitomo Mitsui Trust Group Inc. raised its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 21.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,700 shares of the biotechnology company’s stock after buying an additional 300 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Sarepta Therapeutics were worth $212,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the company. Capital International Investors raised its stake in shares of Sarepta Therapeutics by 1.6% in the first quarter. Capital International Investors now owns 4,817,517 shares of the biotechnology company’s stock valued at $623,676,000 after buying an additional 76,032 shares during the period. Farallon Capital Management LLC grew its position in shares of Sarepta Therapeutics by 102.8% in the first quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock valued at $317,630,000 after purchasing an additional 1,243,427 shares in the last quarter. Thrivent Financial for Lutherans grew its position in shares of Sarepta Therapeutics by 6.3% in the second quarter. Thrivent Financial for Lutherans now owns 644,675 shares of the biotechnology company’s stock valued at $101,858,000 after purchasing an additional 37,940 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its position in shares of Sarepta Therapeutics by 26.3% in the first quarter. Jacobs Levy Equity Management Inc. now owns 579,637 shares of the biotechnology company’s stock valued at $75,040,000 after purchasing an additional 120,535 shares in the last quarter. Finally, abrdn plc grew its position in shares of Sarepta Therapeutics by 30.7% in the third quarter. abrdn plc now owns 431,098 shares of the biotechnology company’s stock valued at $53,935,000 after purchasing an additional 101,253 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on SRPT shares. UBS Group lifted their price target on Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th. Royal Bank of Canada reiterated an “outperform” rating and issued a $182.00 price target on shares of Sarepta Therapeutics in a research report on Monday, October 21st. Robert W. Baird reduced their price target on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Cantor Fitzgerald upgraded Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $152.00 to $167.00 in a research report on Thursday, November 7th. Finally, Needham & Company LLC restated a “buy” rating and set a $205.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, November 7th. Two analysts have rated the stock with a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $181.33.

Sarepta Therapeutics Trading Up 4.0 %

NASDAQ SRPT opened at $110.86 on Thursday. Sarepta Therapeutics, Inc. has a 1-year low of $78.67 and a 1-year high of $173.25. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The stock has a 50-day moving average of $122.50 and a 200-day moving average of $131.85. The firm has a market cap of $10.59 billion, a PE ratio of 88.69 and a beta of 0.81.

Insider Activity

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the transaction, the chief financial officer now owns 33,946 shares of the company’s stock, valued at $4,662,822.56. This represents a 14.99 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 7.70% of the stock is currently owned by corporate insiders.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.